Journal of Clinical Oncology, Vol 12, 1541-1546, Copyright © 1994 by American Society of Clinical Oncology
Clinical significance of t(14; 18)-positive cells in the circulation of patients with stage III or IV follicular non-Hodgkin's lymphoma during first remission
AC Lambrechts, PE Hupkes, LC Dorssers and MB van't Veer
Department of Molecular Biology, Dr Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
PURPOSE: To evaluate polymerase chain reaction (PCR) analysis as a method
for the detection of circulating lymphoma cells in patients with stage III
and IV t(14; 18)-positive follicular Non-Hodgkin's lymphoma (NHL) in first
remission in a longitudinal prospective study. PATIENTS AND METHODS:
Peripheral blood or bone marrow from eight patients with stage III and IV
t(14; 18)-positive NHL was studied using PCR to detect the presence of
t(14; 18)-positive cells in the circulation at different times during first
remission. RESULTS: In four of six patients with no clinical evidence of
disease (NCED), t(14; 18)- positive cells were detectable in the
circulation. In one of two patients with clinical evidence of disease
(CED), no t(14; 18)-positive cells were found at the four different
occasions tested during first remission. First-remission duration ranged
from 17 to 81+ months. The duration from the first PCR determination in
remission until first relapse or the end of the observation period ranged
from 10 to 37+ months. CONCLUSION: In patients with t(14; 18)-positive
follicular NHL stage III and IV, treated with conventional remission
induction therapy, the presence or absence of t(14; 18)-positive cells in
the circulation shows no obvious correlation with the clinical remission
status and the remission duration.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Rambaldi, E. Carlotti, E. Oldani, I. D. Starza, M. Baccarani, S. Cortelazzo, F. Lauria, L. Arcaini, E. Morra, A. Pulsoni, et al.
Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma
Blood,
May 1, 2005;
105(9):
3428 - 3433.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Fernandez-Ruiz, M. Cabrerizo, M. Ortega, C. Blas, P. Llamas, M. Santos-Roncero, S. Nieto, A. Acevedo, G. Perez, C. Nicolas, et al.
High Molecular Response Rate and Clinical Correlation in Patients with Follicular Lymphoma Treated with Cyclophosphamide-Vincristine-Prednisone plus Interferon {alpha} 2b
Clin. Cancer Res.,
July 1, 2003;
9(7):
2497 - 2503.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Biagi and J. F. Seymour
Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation
Blood,
May 29, 2002;
99(12):
4265 - 4275.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. P. W. Mandigers, J. P. P. Meijerink, E. J. B. M. Mensink, E. L. R. T. M. Tonnissen, K. M. Hebeda, M. J. J. T. Bogman, and J. M. M. Raemaekers
Lack of correlation between numbers of circulating t(14;18)-positive cells and response to first-line treatment in follicular lymphoma
Blood,
August 15, 2001;
98(4):
940 - 944.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Lopez-Guillermo, F. Cabanillas, P. McLaughlin, T. Smith, F. Hagemeister, M. A. Rodriguez, J. E. Romaguera, A. Younes, A. H. Sarris, H. A. Preti, et al.
The Clinical Significance of Molecular Response in Indolent Follicular Lymphomas
Blood,
April 15, 1998;
91(8):
2955 - 2960.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. Jennings and K. A. Foon
Recent Advances in Flow Cytometry: Application to the Diagnosis of Hematologic Malignancy
Blood,
October 15, 1997;
90(8):
2863 - 2892.
[Full Text]
[PDF]
|
|
|
|
